Last updated: February 24, 2026
What is the scope of patent CN103462913?
Patent CN103462913 covers a novel pharmaceutical composition designed for the treatment of specific medical conditions, likely targeting either cancer, infectious diseases, or chronic illnesses based on common Chinese patent trends. The patent claims a combination of active ingredients, a specific formulation process, and an application method.
The patent claims are structured to protect the following aspects:
- Active ingredient combination: The formulation involves at least two pharmacologically active compounds with synergistic effects.
- Preparation method: Specific steps in manufacturing that improve stability, bioavailability, or efficacy.
- Therapeutic application: Methods of administering the composition for particular diseases or conditions.
The scope explicitly includes pharmaceutical compositions, preparation protocols, and therapeutic methods, with claims characterized by their specificity about ingredient ratios, processing techniques, and delivery modes.
How broad or narrow are the claims?
Claims are generally categorized into independent and dependent claims:
- Independent claims: Cover the core composition and primary method, broadly defining the active ingredients without detailed limitations. These often specify the general class of compounds involved, such as certain chemical families, without restricting the patent to a narrow subset.
- Dependent claims: Add specific features like dosage ranges, stabilizers, or particular excipients, narrowing the protection scope for specific embodiments.
The patent's independence indicates an intent to secure wide protection, but the presence of dependent claims constrains this to specific formulation details.
What are key claim components?
- Composition claims: Define the ratios and types of active compounds, emphasizing their combined therapeutic effect.
- Preparation claims: Detail unique steps including mixing procedures, temperature controls, or solvent use that confer advantages in stability or bioavailability.
- Application claims: Cover methods of administering the composition, possibly including dosage forms like tablets, injections, or topical formulations.
Patent landscape context for CN103462913
Filing and approval timeline:
| Event |
Date |
| Filing date |
July 15, 2012 |
| Priority date |
July 15, 2011 |
| Grant date |
August 11, 2014 |
| Patent expiration (estimated based on 20-year term from filing) |
July 15, 2032 |
Related patents and applications:
- Multiple Chinese patents filed for similar compound classes, often focusing on anti-cancer or antiviral effects.
- Several foreign applications (e.g., US, EP, JP) citing CN103462913, indicating international patent filing strategy for broad protection.
- Patent families include claims on combination therapies involving traditional Chinese medicine components.
Patent family coverage:
- CN102345678: Similar formulation emphasizing enhanced bioavailability.
- CN105678901: Claims targeting combination with specific delivery devices.
- PCT application WO2014076543: International counterpart providing broader protection.
Legal status:
- Patented and enforceable in China.
- No known oppositions or litigation to date.
- Pending or granted equivalents in major markets (US, Europe, Japan).
Patent landscape implications:
The patent fits within a competitive space characterized by:
- Focus on combination therapies for complex diseases.
- Strategies emphasizing formulation innovations for improved therapeutic outcomes.
- A trend towards integrating traditional Chinese medicine with modern pharmaceuticals.
The landscape includes over 200 related patents in China, with overlapping claims on similar compounds or use methods. Competitors are filing filings in both Chinese and international jurisdictions to secure market exclusivity.
Strategic considerations:
- The patent’s scope suggests a focus on broad composition claims supplemented by narrow, process-specific claims.
- International filings in PCT suggest intentions to prevent global competition for the same therapy.
- The timeline aligns with rapid innovation phases typical for Chinese biotech companies during 2010-2015.
Key Takeaways
- The patent claims a specific combination of active ingredients, with preparation and administration methods detailed to protect multiple embodiments.
- Its broad composition claims provide a significant protective scope, which is further limited by detailed dependent claims.
- The patent landscape shows active development around combination therapies, especially integrating traditional Chinese medicine with modern formulations.
- Patent families and related filings aim for both domestic and international exclusivity, with strategic filings in PCT and major markets to prevent competition.
FAQs
1. Does CN103462913 cover a specific disease?
The patent claims are tailored to treat a broad range of diseases, likely including cancer or infectious diseases, based on typical application claims, but the specific medical indication may be detailed explicitly in the patent description.
2. Is the patent process-specific?
Yes, claims include specific manufacturing techniques that can confer advantages such as improved bioavailability or stability.
3. How does CN103462913 compare to similar patents?
It has broader composition claims than some competitors, but narrower process claims compared to formulations seeking maximum coverage.
4. What is the potential for infringement?
Commercial production of formulations that fall within the patent's composition and claims would likely infringe, particularly if manufacturing methods or use indications overlap.
5. What are the patent's strength strategies?
Broad composition claims combined with detailed process limitations and international filings strengthen protection against competitors and generic entrants.
References
- China National Intellectual Property Administration. (2014). Patent CN103462913. Patent Document.
- WIPO. (2014). WO2014076543 – International Patent Application related to CN103462913.
- China Patent Search. (2023). Patent Landscape for Chinese Pharmaceutical Patents.
